<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03694821</url>
  </required_header>
  <id_info>
    <org_study_id>18-093-1</org_study_id>
    <nct_id>NCT03694821</nct_id>
  </id_info>
  <brief_title>Knee Injection RCT</brief_title>
  <official_title>Efficacy and Cost-effectiveness of Intra-Articular Ketorolac Injection for Knee Osteoarthritis: A Randomized, Controlled, Double-Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthopedic Research and Education Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Ketorolac injection is a cost-effective adjunct in the nonoperative treatment of
      knee osteoarthritis (OA) compared to steroids and viscosupplementation.

      Aims/objectives: The objective of this randomized, controlled, double-blinded, prospective
      study is to assess the efficacy and cost-effectiveness of knee injection with ketorolac in
      the nonsurgical management of symptomatic OA compared to injections with corticosteroids and
      viscosupplements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to examine the effectiveness of intra-articular (inside
      the joint) ketorolac injection compared to injection with either corticosteroid or hyaluronic
      acid for the treatment of painful knee osteoarthritis. Patients will be randomly assigned to
      receive either ketorolac (a nonsteroidal anti-inflammatory drug, methylprednisolone (a
      steroid), hyaluronic acid (a substance that is naturally present in the human body).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment
  </why_stopped>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Actual">July 16, 2019</completion_date>
  <primary_completion_date type="Actual">July 16, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Pain Scale (VAS)</measure>
    <time_frame>3 months post injection</time_frame>
    <description>average knee pain between 0 (no pain) and 10 (worst pain) 3 months following injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</measure>
    <time_frame>3 and 6 months post injection</time_frame>
    <description>self-reported pain, stiffness and functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Knee Questionnaire</measure>
    <time_frame>3 and 6 months post injection</time_frame>
    <description>self-reported pain, stiffness and functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Koos, Jr. Knee Survey</measure>
    <time_frame>3 and 6 months post injection</time_frame>
    <description>self-reported pain, stiffness and functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Pain Scale (VAS)</measure>
    <time_frame>6 months</time_frame>
    <description>average knee pain between 0 (no pain) and 10 (worst pain) 6 months following injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>3 and 6 months post injection</time_frame>
    <description>satisfaction with treatment rated as &quot;Yes&quot; or &quot;No&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-routine Visits Due to Inadequate Pain Relief or Complications</measure>
    <time_frame>3 months post injection</time_frame>
    <description>Any additional visits due to inadequate pain relief or complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of Intervention</measure>
    <time_frame>3 months post injection</time_frame>
    <description>cost of each injection</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One knee injection of Hylan G-F 20 (Synvisc-One)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine Injection</intervention_name>
    <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <other_name>Ketorolac Tromethamine; NDC 63323-162-02; J Code J1885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone Acetate Injection</intervention_name>
    <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
    <arm_group_label>Corticosteroid</arm_group_label>
    <other_name>DEPO-MEDROL; NDC 0009-3073-01; J Code J1030</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylan G-F 20</intervention_name>
    <description>One knee injection of Hylan G-F 20 (Synvisc-One)</description>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <other_name>Synvisc-One; NDC 58468-0090-03; J Code J7325</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over the age of 18 who present with 1) symptomatic knee OA and radiographic
             evidence of joint space narrowing and 2) are interested in knee injections for pain
             relief.

        Exclusion Criteria:

          -  Prior injections into the same knee within the past 6 months,

          -  Pregnant and/or lactating women,

          -  Inflammatory joint disease including rheumatoid or psoriatic arthritis,

          -  Concurrent use of anti-rheumatic drugs,

          -  Allergy or hypersensitivity to the study medications,

          -  Patients on an active pain management contract,

          -  Patients with insurance that requires pre-certification for any of the study drugs,

          -  Inability to make own decisions regarding the informed consent,

          -  Inability to read and/or understand English,

          -  Patients who are unable to return for follow-up or be reached by phone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad J. Halawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UConn Health</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet. 2005 Mar 12-18;365(9463):965-73. Review.</citation>
    <PMID>15766999</PMID>
  </reference>
  <reference>
    <citation>Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006 Jan;54(1):226-9.</citation>
    <PMID>16385518</PMID>
  </reference>
  <reference>
    <citation>Bone and Joint Initiative: The Burden of Musculoskeletal Diseases in the United States. http://www.boneandjointburden.org/2014-report/ivh12/osteoarthritis-and-allied-disorders</citation>
  </reference>
  <reference>
    <citation>Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. 2013 Sep;21(9):571-6. doi: 10.5435/JAAOS-21-09-571. Review.</citation>
    <PMID>23996988</PMID>
  </reference>
  <reference>
    <citation>Gray RG, Gottlieb NL. Intra-articular corticosteroids. An updated assessment. Clin Orthop Relat Res. 1983 Jul-Aug;(177):235-63. Review.</citation>
    <PMID>6345042</PMID>
  </reference>
  <reference>
    <citation>Hunter DJ. Viscosupplementation for osteoarthritis of the knee. N Engl J Med. 2015 Mar 12;372(11):1040-7. doi: 10.1056/NEJMct1215534. Review.</citation>
    <PMID>25760356</PMID>
  </reference>
  <reference>
    <citation>van der Weegen W, Wullems JA, Bos E, Noten H, van Drumpt RA. No difference between intra-articular injection of hyaluronic acid and placebo for mild to moderate knee osteoarthritis: a randomized, controlled, double-blind trial. J Arthroplasty. 2015 May;30(5):754-7. doi: 10.1016/j.arth.2014.12.012. Epub 2014 Dec 13.</citation>
    <PMID>25548079</PMID>
  </reference>
  <reference>
    <citation>Campbell KA, Erickson BJ, Saltzman BM, Mascarenhas R, Bach BR Jr, Cole BJ, Verma NN. Is Local Viscosupplementation Injection Clinically Superior to Other Therapies in the Treatment of Osteoarthritis of the Knee: A Systematic Review of Overlapping Meta-analyses. Arthroscopy. 2015 Oct;31(10):2036-45.e14. doi: 10.1016/j.arthro.2015.03.030. Epub 2015 May 19. Review.</citation>
    <PMID>25998016</PMID>
  </reference>
  <reference>
    <citation>Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013 Jan;21(1):16-21. doi: 10.1016/j.joca.2012.11.012. Epub 2012 Nov 27. Review.</citation>
    <PMID>23194896</PMID>
  </reference>
  <reference>
    <citation>Brown GA. AAOS clinical practice guideline: treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. 2013 Sep;21(9):577-9. doi: 10.5435/JAAOS-21-09-577.</citation>
    <PMID>23996989</PMID>
  </reference>
  <reference>
    <citation>Reuben SS, Connelly NR. Postoperative analgesia for outpatient arthroscopic knee sugery with intraarticular bupivacaine and ketorolac. Anesth Analg. 1995 Jun;80(6):1154-7.</citation>
    <PMID>7762844</PMID>
  </reference>
  <reference>
    <citation>Desai A, Ramankutty S, Board T, Raut V. Does intraarticular steroid infiltration increase the rate of infection in subsequent total knee replacements? Knee. 2009 Aug;16(4):262-4. doi: 10.1016/j.knee.2008.12.002. Epub 2009 Jan 12.</citation>
    <PMID>19138855</PMID>
  </reference>
  <reference>
    <citation>Jones AC, Pattrick M, Doherty S, Doherty M. Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Osteoarthritis Cartilage. 1995 Dec;3(4):269-73.</citation>
    <PMID>8689462</PMID>
  </reference>
  <reference>
    <citation>Leardini G, Mattara L, Franceschini M, Perbellini A. Intra-articular treatment of knee osteoarthritis. A comparative study between hyaluronic acid and 6-methyl prednisolone acetate. Clin Exp Rheumatol. 1991 Jul-Aug;9(4):375-81.</citation>
    <PMID>1934686</PMID>
  </reference>
  <reference>
    <citation>Bellamy JL, Goff BJ, Sayeed SA. Economic Impact of Ketorolac vs Corticosteroid Intra-Articular Knee Injections for Osteoarthritis: A Randomized, Double-Blind, Prospective Study. J Arthroplasty. 2016 Sep;31(9 Suppl):293-7. doi: 10.1016/j.arth.2016.05.015. Epub 2016 May 18.</citation>
    <PMID>27402605</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <results_first_submitted>October 1, 2019</results_first_submitted>
  <results_first_submitted_qc>February 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2020</results_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <keyword>Injection</keyword>
  <keyword>Ketorolac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03694821/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketorolac</title>
          <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Ketorolac Tromethamine Injection: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
        </group>
        <group group_id="P2">
          <title>Corticosteroid</title>
          <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Methylprednisolone Acetate Injection: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
        </group>
        <group group_id="P3">
          <title>Hyaluronic Acid</title>
          <description>One knee injection of Hylan G-F 20 (Synvisc-One)
Hylan G-F 20: One knee injection of Hylan G-F 20 (Synvisc-One)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only age, sex, race and ethnicity data available. No other analysis completed due to study termination.</population>
      <group_list>
        <group group_id="B1">
          <title>Ketorolac</title>
          <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Ketorolac Tromethamine Injection: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
        </group>
        <group group_id="B2">
          <title>Corticosteroid</title>
          <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Methylprednisolone Acetate Injection: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
        </group>
        <group group_id="B3">
          <title>Hyaluronic Acid</title>
          <description>One knee injection of Hylan G-F 20 (Synvisc-One)
Hylan G-F 20: One knee injection of Hylan G-F 20 (Synvisc-One)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Pain Scale (VAS)</title>
        <description>average knee pain between 0 (no pain) and 10 (worst pain) 3 months following injection</description>
        <time_frame>3 months post injection</time_frame>
        <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Ketorolac Tromethamine Injection: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Methylprednisolone Acetate Injection: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O3">
            <title>Hyaluronic Acid</title>
            <description>One knee injection of Hylan G-F 20 (Synvisc-One)
Hylan G-F 20: One knee injection of Hylan G-F 20 (Synvisc-One)</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Pain Scale (VAS)</title>
          <description>average knee pain between 0 (no pain) and 10 (worst pain) 3 months following injection</description>
          <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</title>
        <description>self-reported pain, stiffness and functioning</description>
        <time_frame>3 and 6 months post injection</time_frame>
        <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Ketorolac Tromethamine Injection: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Methylprednisolone Acetate Injection: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O3">
            <title>Hyaluronic Acid</title>
            <description>One knee injection of Hylan G-F 20 (Synvisc-One)
Hylan G-F 20: One knee injection of Hylan G-F 20 (Synvisc-One)</description>
          </group>
        </group_list>
        <measure>
          <title>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</title>
          <description>self-reported pain, stiffness and functioning</description>
          <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxford Knee Questionnaire</title>
        <description>self-reported pain, stiffness and functioning</description>
        <time_frame>3 and 6 months post injection</time_frame>
        <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Ketorolac Tromethamine Injection: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Methylprednisolone Acetate Injection: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O3">
            <title>Hyaluronic Acid</title>
            <description>One knee injection of Hylan G-F 20 (Synvisc-One)
Hylan G-F 20: One knee injection of Hylan G-F 20 (Synvisc-One)</description>
          </group>
        </group_list>
        <measure>
          <title>Oxford Knee Questionnaire</title>
          <description>self-reported pain, stiffness and functioning</description>
          <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Koos, Jr. Knee Survey</title>
        <description>self-reported pain, stiffness and functioning</description>
        <time_frame>3 and 6 months post injection</time_frame>
        <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Ketorolac Tromethamine Injection: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Methylprednisolone Acetate Injection: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O3">
            <title>Hyaluronic Acid</title>
            <description>One knee injection of Hylan G-F 20 (Synvisc-One)
Hylan G-F 20: One knee injection of Hylan G-F 20 (Synvisc-One)</description>
          </group>
        </group_list>
        <measure>
          <title>Koos, Jr. Knee Survey</title>
          <description>self-reported pain, stiffness and functioning</description>
          <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Pain Scale (VAS)</title>
        <description>average knee pain between 0 (no pain) and 10 (worst pain) 6 months following injection</description>
        <time_frame>6 months</time_frame>
        <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Ketorolac Tromethamine Injection: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Methylprednisolone Acetate Injection: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O3">
            <title>Hyaluronic Acid</title>
            <description>One knee injection of Hylan G-F 20 (Synvisc-One)
Hylan G-F 20: One knee injection of Hylan G-F 20 (Synvisc-One)</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Pain Scale (VAS)</title>
          <description>average knee pain between 0 (no pain) and 10 (worst pain) 6 months following injection</description>
          <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>satisfaction with treatment rated as &quot;Yes&quot; or &quot;No&quot;</description>
        <time_frame>3 and 6 months post injection</time_frame>
        <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Ketorolac Tromethamine Injection: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Methylprednisolone Acetate Injection: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O3">
            <title>Hyaluronic Acid</title>
            <description>One knee injection of Hylan G-F 20 (Synvisc-One)
Hylan G-F 20: One knee injection of Hylan G-F 20 (Synvisc-One)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>satisfaction with treatment rated as &quot;Yes&quot; or &quot;No&quot;</description>
          <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-routine Visits Due to Inadequate Pain Relief or Complications</title>
        <description>Any additional visits due to inadequate pain relief or complications</description>
        <time_frame>3 months post injection</time_frame>
        <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Ketorolac Tromethamine Injection: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Methylprednisolone Acetate Injection: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O3">
            <title>Hyaluronic Acid</title>
            <description>One knee injection of Hylan G-F 20 (Synvisc-One)
Hylan G-F 20: One knee injection of Hylan G-F 20 (Synvisc-One)</description>
          </group>
        </group_list>
        <measure>
          <title>Non-routine Visits Due to Inadequate Pain Relief or Complications</title>
          <description>Any additional visits due to inadequate pain relief or complications</description>
          <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost of Intervention</title>
        <description>cost of each injection</description>
        <time_frame>3 months post injection</time_frame>
        <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac</title>
            <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Ketorolac Tromethamine Injection: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
Methylprednisolone Acetate Injection: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
          </group>
          <group group_id="O3">
            <title>Hyaluronic Acid</title>
            <description>One knee injection of Hylan G-F 20 (Synvisc-One)
Hylan G-F 20: One knee injection of Hylan G-F 20 (Synvisc-One)</description>
          </group>
        </group_list>
        <measure>
          <title>Cost of Intervention</title>
          <description>cost of each injection</description>
          <population>Data were collected, but the PI has left the institution. All efforts to locate and analyze the data have been exhausted; therefore no data are available to report.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Same definition was used.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ketorolac</title>
          <description>One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
        </group>
        <group group_id="E2">
          <title>Corticosteroid</title>
          <description>One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine</description>
        </group>
        <group group_id="E3">
          <title>Hyaluronic Acid</title>
          <description>One knee injection of Hylan G-F 20 (Synvisc-One)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Outcomes, Research &amp; Quality</name_or_title>
      <organization>UConn Health</organization>
      <phone>860-679-4932</phone>
      <email>mcote@uchc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

